On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did they fail? And what does this mean for the development of new heart medicines moving forward? Cardiologist and biotech entrepreneur Ethan Weiss joins us to discuss the surprising failures and long-term implications of two large clinical trials involving drugs developed from Novo Nordisk and Novartis, respectively. Plus, we have a recap of biotech news we missed while on hiatus, including a spurt of FDA drug approvals and the next big thing in cancer treatment from Merck and Moderna.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Readout Loud
Definium's new psychedelics data, and a reprieve for international scientists
411: Capricor's data clash and a fugitive in the C-suite
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
Get summaries like this every morning.
Free AI-powered recaps of The Readout Loud and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.